A Novel Anti-Kv10.1 Nanobody Fused to Single-Chain TRAIL Enhances Apoptosis Induction in Cancer Cells
Open Access
- 14 May 2020
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 11, 686
Abstract
Antibody-based therapies hold promise for a safe and efficient treatment of cancer. The identification of target tumor cells through a specific antigen enriched on their surface and the subsequent delivery of the therapeutic agent only to those cells requires, besides the efficacy of the therapeutic agent itself, the identification of an antigen enriched on the surface of tumor cells, the generation of high affinity antibodies against that antigen. We have generated single-domain antibodies (nanobodies) against the voltage-gated potassium channel Kv10.1, which outside of the brain is detectable almost exclusively in tumor cells. The nanobody with highest affinity was fused to an improved form of the tumor necrosis factor-related apoptosis inducing ligand TRAIL, to target this cytokine to the surface of tumor cells. The resulting construct, VHH-D9-scTRAIL, shows rapid and strong apoptosis induction in different tumor models in cell culture. The construct combines two sources of specificity, the expression of the antigen restricted to tumor cells and the tumor selectivity of TRAIL. Such specificity combined with the high affinity obtained through nanobodies make the novel agent a promising concept for cancer therapy.Keywords
Funding Information
- Max-Planck-Gesellschaft
- H2020 Marie Skłodowska-Curie Actions
- FP7 Nanosciences, Nanotechnologies, Materials and new Production Technologies
This publication has 49 references indexed in Scilit:
- Nanobodies: Natural Single-Domain AntibodiesAnnual Review of Biochemistry, 2013
- MicroRNA-34a Inhibits Human Osteosarcoma Proliferation by Downregulating Ether à go-go 1 ExpressionInternational Journal of Medical Sciences, 2013
- Correction: Transcriptional and Post-Transcriptional Mechanisms for Oncogenic Overexpression of Ether À Go-Go K+ChannelPLOS ONE, 2011
- Tumor cell-selective apoptosis induction through targeting of KV10.1 via bifunctional TRAIL antibodyMolecular Cancer, 2011
- Transcriptional and Post-Transcriptional Mechanisms for Oncogenic Overexpression of Ether À Go-Go K+ ChannelPLOS ONE, 2011
- Eag1 Expression Interferes with Hypoxia Homeostasis and Induces Angiogenesis in TumorsJournal of Biological Chemistry, 2008
- Targeted delivery of a designed sTRAIL mutant results in superior apoptotic activity towards EGFR-positive tumor cellsJournal of Molecular Medicine, 2008
- Monoclonal Antibody Blockade of the Human Eag1 Potassium Channel Function Exerts Antitumor ActivityCancer Research, 2007
- Immortalization of pancreatic stellate cells as an in vitro model of pancreatic fibrosis: deactivation is induced by matrigel and N-acetylcysteineLaboratory Investigation, 2005
- Safety and antitumor activity of recombinant soluble Apo2 ligandJournal of Clinical Investigation, 1999